Technetium (99mTc) tilmanocept
Technetium (99mTc) tilmanocept, trade name Lymphoseek, is a radiopharmaceutical diagnostic imaging agent approved by the U.S. Food and Drug Administration (FDA) for the imaging of lymph nodes.[1][2] It is used to locate those lymph nodes which may be draining from tumors, and assist doctors in locating those lymph nodes for removal during surgery.[3]
Clinical data | |
---|---|
Trade names | Lymphoseek |
AHFS/Drugs.com | lymphoseek |
Pregnancy category |
|
Routes of administration | Intradermal, subcutaneous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 1.75 to 3.05 hours at injection site |
Identifiers | |
| |
KEGG | |
Chemical and physical data | |
Formula | (C6H10O5)n(C19H28N4O9S99mTc)3–8(C13H24N2O5S2)12–20(C5H11NS)0–17 |
Molar mass | 15,281–23,454 g/mol[1] |
References
- FDA Professional Drug Information
- "FDA approves Lymphoseek to help locate lymph nodes in patients with certain cancers". U.S. Food and Drug Administration. Archived from the original on 30 March 2014.
- Marcinow AM, Hall N, Byrum E, Teknos TN, Old MO, Agrawal A (September 2013). "Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: initial institutional report in an ongoing phase 3 study". JAMA Otolaryngology–Head & Neck Surgery. 139 (9): 895–902. doi:10.1001/jamaoto.2013.4239. PMC 4301415. PMID 24051744.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.